NCT04542226 - Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2020

Primary Completion Date

July 15, 2020

Study Completion Date

October 30, 2020

Conditions

Infections, Coronavirus

Interventions

DRUG

Polyoxidonium

Polyoxidonium (azoximer bromide) is administered in the dose of 12 mg (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections)

Trial Locations (5)

230030

"Healthcare Institution Grodno Regional Infectious Clinical Hospital", Grodno

353915

"State-Funded Healthcare Institution Infectious Disease Hospital No.3 of Ministry of Health of Krasnodar Krai", Novorossiysk

396310

"State-Funded Healthcare Institution of Voronezh Region Novaya Usman District Hospital", Novaya Usman'

424005

"State-Funded Institution of Mari El Republic Yoshkar-Ola City Hospital", Yoshkar-Ola

428017

"State-Funded Healthcare Institution Emergency Hospital of Ministry of Health of Chuvash Republic", Cheboksary

All Listed Sponsors

lead

NPO Petrovax

INDUSTRY